Home
ARQT
ARQT News

Latest Arcutis Biotherapeutics Inc. (ARQT) News on July 26, 2024

MT Newswires

3 days ago

Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswire

3 days ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

GlobeNewswire

4 days ago

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Zacks

7 days ago

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Zacks

9 days ago

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Zacks

10 days ago

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Zacks

11 days ago

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Zacks

14 days ago

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Zacks

14 days ago

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Zacks

14 days ago

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Arcutis bags FDA approval for atopic dermatitis cream after delay

Pharmaceutical Technology

16 days ago

Arcutis bags FDA approval for atopic dermatitis cream after delay

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

16 days ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

Benzinga

16 days ago

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

AbbVie names new R&D head; Arcutis eczema cream approved

BioPharma Dive

17 days ago

AbbVie names new R&D head; Arcutis eczema cream approved

MT Newswires

17 days ago

Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

GlobeNewswire

17 days ago

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

GlobeNewswire

17 days ago

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

23 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investor's Business Daily

25 days ago

Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Zacks

25 days ago

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

Zacks

a month ago

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Zacks

a month ago

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Zacks

a month ago

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Zacks

a month ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Zacks

a month ago

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet

Zacks

a month ago

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Zacks

a month ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Zacks

a month ago

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Zacks

a month ago

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Zacks

a month ago

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires

2 months ago

Arcutis Biotherapeutics Says Experimental Cream Showed Improvements in Atopic Dermatitis Symptoms

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

GlobeNewswire

2 months ago

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Zacks

2 months ago

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

Zacks

2 months ago

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

GlobeNewswire

2 months ago

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Zacks

2 months ago

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

2 months ago

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Zacks

2 months ago

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Zacks

2 months ago

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Zacks

2 months ago

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Zacks

2 months ago

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Zacks

2 months ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

Zacks

2 months ago

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week

Simply Wall St.

2 months ago

Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

Zacks

2 months ago

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade

Zacks

2 months ago

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade

MT Newswires

2 months ago

Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise

Thomson Reuters StreetEvents

2 months ago

Q1 2024 Arcutis Biotherapeutics Inc Earnings Call

MT Newswires

2 months ago

Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

MT Newswires

2 months ago

Sector Update: Health Care

MT Newswires

2 months ago

Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating

MT Newswires

2 months ago

Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket

GuruFocus.com

2 months ago

Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...

MT Newswires

2 months ago

Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

GlobeNewswire

2 months ago

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire

3 months ago

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts

Simply Wall St.

3 months ago

Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Zacks

3 months ago

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Arcutis Appoints David Topper as Chief Financial Officer

GlobeNewswire

4 months ago

Arcutis Appoints David Topper as Chief Financial Officer

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

GlobeNewswire

4 months ago

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

4 months ago

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks

4 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Zacks

4 months ago

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Zacks

4 months ago

Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

GlobeNewswire

5 months ago

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

GlobeNewswire

5 months ago

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

GlobeNewswire

5 months ago

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors

Barrons.com

5 months ago

Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire

5 months ago

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

GlobeNewswire

5 months ago

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Zacks

5 months ago

Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?

Zacks

5 months ago

Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?

Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.

5 months ago

Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

5 months ago

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Simply Wall St.

5 months ago

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Announces Pricing of $150 Million Public Offering

GlobeNewswire

5 months ago

Arcutis Announces Pricing of $150 Million Public Offering

Arcutis Announces Proposed Public Offering

GlobeNewswire

5 months ago

Arcutis Announces Proposed Public Offering

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

GlobeNewswire

5 months ago

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis Biotherapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Arcutis Biotherapeutics Full Year 2023 Earnings: Beats Expectations

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Arcutis Biotherapeutics Inc Earnings Call

Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023

GuruFocus.com

5 months ago

Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

5 months ago

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?

Zacks

5 months ago

Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Zacks

6 months ago

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Steven Cohen's Point72 Asset Management Acquires New Stake in Arcutis Biotherapeutics Inc

GuruFocus.com

6 months ago

Steven Cohen's Point72 Asset Management Acquires New Stake in Arcutis Biotherapeutics Inc

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

GlobeNewswire

6 months ago

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

DoubleDown Interactive to Report 2023 Fourth Quarter and Full Year Financial Results on February 13 and Host Conference Call and Webcast

GlobeNewswire

6 months ago

DoubleDown Interactive to Report 2023 Fourth Quarter and Full Year Financial Results on February 13 and Host Conference Call and Webcast

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Zacks

6 months ago

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Share on Social Networks: